AJN, American Journal of Nursing
Cure8 news brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Ulcerative colitis, Golimumab, Biosimilars, and Anti-TNF. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAJN, American Journal of Nursing
PublisherOvid Technologies (Wolters Kluwer Health)
AuthorsDiane S. Aschenbrenner
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 20, 2026, 12:00 AM
Content availableMetadata only
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Biocon Biologics Launches YESINTEK in U.S. for Autoimmune Diseases
Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Guselkumab.
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.